MAP2K7 and Hepatic fibrosis: This study suggested that MCL effectively ameliorated hepatic fibrosis by targeting TrxR1 and TrxR2, thereby enhancing ROS production, activating the MEK/ERK pathway, and inhibiting HSC autophagy (Figure 8).